

10 clinical milestones

CNS

Vimpat®	epilepsy monotherapy (EU) – start of Phase 3 (Dec. 2010)
Brivaracetam	epilepsy adjunctive therapy – start of third Phase 3 trial (Dec. 2010)
Vimpat®	epilepsy PGTCS – start of Phase 2 (May 2010)
UCB2892	cognitive disorders – start of Phase I (Mar. 2010) - project discontinued (Jan. 2011)
UCB0942	drug refractory epilepsy – start of Phase I (Dec. 2010)

IMMUNOLOGY

Cimzia®	psoriatic arthritis – start of Phase 3 (Mar. 2010)
Cimzia®	ankylosing spondylitis – start of Phase 3 (Mar. 2010)
Epratuzumab	systemic lupus erythematosus – start of Phase 3 (Dec. 2010)
Olokizumab	rheumatoid arthritis – start of Phase 2b (Dec. 2010)
CDP7567	systemic lupus erythematosus – start of Phase I (Apr. 2010)

approximately
80
clinical studies

more than
4 000
patients recruited

more than
10 000
patients involved



2010 MILESTONES

2010 was marked by several important milestones. Each one played a major role in our quest to become the patient-centric biopharma leader, helping us deliver our commitments to people living with severe diseases and to our shareholders.

3 regulatory milestones

Xyrem®	fibromyalgia – EU filing (H1 2010)
Keppra®	epilepsy adjunctive therapy – approval in Japan under brand name E Keppra® (July 2010)
Xyzal®	allergy – approval in Japan (Oct. 2010)

FINANCIAL PERFORMANCE AS EXPECTED

€3.2
billion of revenue

€731
million of recurring EBITDA

€1.99
core earnings per share

Cimzia®

- Reaching more than **22 000** patients
- Available in **20** countries
- **16** national launches
- **2** indications:
rheumatoid arthritis
Crohn's disease
- **4** additional development projects:
ankylosing spondylitis
juvenile rheumatoid arthritis
psoriatic arthritis
rheumatoid arthritis (Japan)

Vimpat®

- Reaching more than **108 000** patients
- Available in **22** countries
- **7** national launches
- **1** indication:
epilepsy adjunctive therapy
- **4** additional development projects:
adjunctive therapy PGTCs
monotherapy (Europe and U.S.)
paediatric adjunctive therapy

Neupro®

- Reaching more than **73 000** patients
- Available in **20** countries
- **4** national launches
- **2** indications:
Parkinson's disease
restless legs syndrome

203 000 patients using new UCB products

22 000 patients treated with Cimzia®

108 000 patients treated with Vimpat®

73 000 patients treated with Neupro®